Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC

• XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
• Laying out demonstration of in vitro bystander and ICD activity
• Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models